Current interpretation for EVAR Trial 1
EVAR had an ongoing 3% better aneurysm-related survival than open repair but no demonstrable all-cause mortality or HRQL benefit. The continuing need for interventions mandates ongoing surveillance and longer follow-up for detailed cost-effectiveness evaluation.